Southern	Santé Sud	REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH					
Health		GENERIC NAME CefTRIAXone					
Effective Date Revised Date:	e: Nov19-2014 : Jan 12 2022	CLASSIFICATION Antibiotic	other names <b>Rocephin</b>	PAGE 1 of 3			
IV bolus IV Infusion IM Injection Subcut	<ul><li>May be administ</li><li>Not recommended</li></ul>	ered by a nurse <b>MINI-BAG PI</b> ered by a nurse	LUS COMPATIBLE				
Available as							
Reconstitutio	Final v IM: Add 2 Final v To red epinep	volume: 10.1 mL 2 mL unpreserved sterile water volume: 2.8 mL uce pain associated with IM, ma	for injection. Shake until drug is Final concentration: 100 mg/r for injection. Shake until drug is Final concentration: 350 mg ay reconstitute with lidocaine 0.3 h lidocaine in children or infants	nL s dissolved. y/mL 5% or 1% without			
IV Bolus:	Dilute to 1	00 mg/mL (preferred) and admi	nister over 3 to 5 minutes				
Intermittent		G PLUS COMPATIBLE ormal saline and infuse over 15	to 60 minutes. Less than or equa	al to 40 mg/mL			
IM:	Administer	deep into a large muscle mass					
DOSAGE:							
-		00 mg per kg per 24 hours divided every 12 to 24 hours num 2 grams in 24 hours)					
Endocarditis Acute Otitis		Load: 75-100 mg/kg					
Infant greater than 30 & Children		Days: 50 mg/kg/24 h given every 24h x 1 dose or 3 days (relapse) (maximum 1 g/dose)					
Gonococcal							
Disseminate	· •	eningitis 10-14 days, Endocardi	• /				
	Neonate: 125mg/dose)		n every 24h (maximum				
	less than 45 kg:		very 24h (maximum 2 g/24h)				
~	• •	to 45 kg: 1 to 2 grams every 24 l					
Conjunctivi	tis:	50 mg/kg/dose x 1 dose	e (maximum 1 g)				



## REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH

# GENERIC NAME

Effective Date: Nov19-2014		CLASSIFICATION Antibiotic	OTHER NAMES	PAGE				
Revised Date: Jan 12 2022			Rocephin	2 of 3				
Renal Impairment: No do norma		losage adjustment required for mild to moderate renal impairment if liver function nal						
Hepatic Impairment:	No dosa	ge adjustment required if renal function normal						
<b>Obesity:</b> Use ide BW –		eal body weight (IBW) OR adjusted body weight (AdBW = IBW + 0.3 (actual IDW))						
Maximum rate: Maximum concentration:	IV: 100	over 5 minutes ) mg/mL 0 mg/mL						
STABILITY/COMPATIBILITY:								
Stability of Final Admixtu	re: 24	nours at room temperature						
Compatibility: Incompatible: IV		mpatible with normal saline, I nger's Lactate	D5W, dextrose- saline combinations					

IM Do not mix with other medications except lidocaine

Refer to King's Compatibility Chart for intravenous admixtures.

### **POTENTIAL HAZARDS:**

- Hypersensitivity: maculopapular or erythematous rash, exfoliative dermatitis, pruritis, eosiniphilia, fever, anaphylaxis (rare)
- GI: nausea, vomiting, diarrhea
- Hemat: hemolytic anemia
- Hepatic: transient elevations in liver enzymes, jaundice, elevations in serum bilirubin
- Metab: reversible biliary pseudolithiasis, displaces bilirubin from albumin binding sites
- Neuro: headache, dizziness
- Renal: elevated BUN and serum creatinine
- Local: phlebitis at IV site; pain at IM site
- Other: rapid administration may produce tachycardia, restlessness, diaphoresis, palpitations

### **CAUTION:**

- not recommended for more than 1 or 2 doses in neonates or patients receiving IV calcium including TPN
- not recommended in infants with severe hyperbilirubinemia (under 1 week or premature) due to increased risk of kernicterus secondary to displacement from plasma protein binding.
- adjust dose in patients with severe renam failure or combined renal and hepatic impairment.
- acute renal impairment especially with consurrnet use of other nephrotoxic drugs (e.g. acyclovir)

Southern Sud	REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH			
Health	GENERIC NAME cefTRIAXone			
Effective Date: Nov19-2014	CLASSIFICATION	OTHER NAMES	PAGE	
Revised Date: Jan 12 2022	Antibiotic	Rocephin	3 for 3	

### **CONTRAINDICATIONS:**

• Allergic reactions to cephalosporin antibiotic

• Neonates less than 46 weeks post-menstrual (corrected) age, except for 1 or 2 doses, due to poor clearance and frequent concurrent administration of parenteral calcium products (including parenteral nutrition).

• Any infant receiving or who reasonably may require IV calcium within 48 hours of IV ceftriaxone. This includes patients receiving parenteral nutrition (containing calcium), continuous calcium-containing infusions, and patients receiving hemodialysis or CRRT (where IV calcium is administered concurrently).

• Warning regarding ceftriaxone and calcium-containing solutions:

- Except in neonates/infants, these may be administered sequentially to one another if the infusion lines are thouroughly flushed between infusions with a compatible fluid.
- Diluents containing calcium, such as Ringer's solutions, are NOT to be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Ceftriaxone must NOT be administered simultaneously with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site, or patients receiving CRRT (where IV calcium is administered concurrently) because precipitation of ceftriaxone-calcium can occur.

**ADDITIONAL NOTES:**